SWAV Add to watchlist
$334.75 0.08 (-0.02%)
After Hours: $334.75 +0.00 (+0.00%)
Last updated: Apr 15, 2026 22:53
52-Week Range
$334.75
$267.80 $334.75 $401.70

Fundamentals Overview

ShockWave Medical, Inc. is in the middle of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 78.8 P/B 18.38 P/S 17.21

Intrinsic value (DCF)

+0% upside vs price

Profitability

Net margin 20.2%

Risk (Beta)

0.88 — in line vol

Earnings & growth

EPS $4.25 Rev +7.8% Profit +24.9% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 39% confidence Risk: Moderate Volatility — Beta 0.88. Diversify and only invest what you can afford to lose.

Pressures (Sell):

Sentiment weakening (7 downgrades)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$12.57B
P/E (TTM)
78.77
EPS (TTM)
$4.25
Dividend Yield
N/A
52-Week Range
$267.80 - $401.70
Volume vs Avg
N/A
Beta
0.88

About

ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascu...
Sector: Healthcare
Headquarters: US
Employees: 1,468
IPO Date: Mar 2019
Beta: 0.88 (Less volatile than market)

Ratings & Grades at a Glance

Recent institutional grades: majority downgrades. Current institutional positions: Buy: 8, Equal Weight: 6, Hold: 3, Market Perform: 1, Neutral: 1, Overweight: 9, Peer Perform: 1, Underperform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $334.75; current price is $334.75. That’s a +0% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 78.77
DCF value (model) $334.75 (0% vs price)
PEG (TTM) N/A
P/B (TTM) 18.38
P/S (TTM) 17.21
P/FCF (TTM) 75.96
Liquidity & enterprise
Current Ratio (TTM) 11.76
Quick Ratio (TTM) 10.73
Cash Ratio (TTM) 3.15
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 20.17%
Gross margin (TTM) 86.94%
Operating margin (TTM) 22.73%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for SWAV.

Analyst Sentiment at a Glance

Sentiment Weakening
Buy 8Equal Weight 6Hold 3Market Perform 1Neutral 1Overweight 9Peer Perform 1Underperform 1
2 upgrades, 7 downgrades
Price Target Consensus
Current $334.75
Median $239.50
Consensus $258.17
Low consensus $175.00
High consensus $360.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Morgan Stanley downgrade Overweight Equal Weight 2024-04-08
Deutsche Bank downgrade Buy Hold 2024-04-08
Leerink Partners downgrade Outperform Market Perform 2024-04-08
CL King downgrade Buy Neutral 2024-04-08
Canaccord Genuity downgrade Buy Hold 2024-04-05
Needham downgrade Buy Hold 2024-04-05
Wolfe Research downgrade Outperform Peer Perform 2024-04-05
Piper Sandler maintain Overweight Overweight 2024-04-02
Needham maintain Buy Buy 2024-02-16
Piper Sandler maintain Overweight Overweight 2024-02-16
Wells Fargo maintain Equal Weight Equal Weight 2024-02-16
Morgan Stanley maintain Overweight Overweight 2023-12-04
Needham maintain Buy Buy 2023-11-07
Morgan Stanley maintain Overweight Overweight 2023-11-07
Needham maintain Buy Buy 2023-10-24
Morgan Stanley maintain Overweight Overweight 2023-08-10
Morgan Stanley maintain Overweight Overweight 2023-08-09
Needham maintain Buy Buy 2023-08-08
Wells Fargo maintain Equal Weight Equal Weight 2023-08-08
Wells Fargo maintain Equal Weight Equal Weight 2023-08-07
Needham maintain Buy Buy 2023-08-07
Morgan Stanley upgrade Equal Weight Overweight 2023-07-10
Morgan Stanley upgrade Equal Weight Overweight 2023-07-09
Piper Sandler maintain Overweight Overweight 2023-05-09
Morgan Stanley maintain Equal Weight Equal Weight 2023-05-09
Wells Fargo maintain Equal Weight Equal Weight 2023-05-09
Needham maintain Buy Buy 2023-05-09
Oppenheimer maintain Underperform Underperform 2023-05-09
Canaccord Genuity maintain Buy Buy 2023-05-09
Deutsche Bank maintain Buy Buy 2023-05-09